CD71 Inhibitors

CD71, also known as transferrin receptor 1 (TfR1), is a transmembrane glycoprotein involved in cellular iron uptake. Its primary function is to bind transferrin, the main iron-transporting protein in the blood, and facilitate the internalization of transferrin-bound iron into cells via receptor-mediated endocytosis. CD71 plays a crucial role in maintaining cellular iron homeostasis, as iron is essential for various cellular processes such as DNA synthesis, energy metabolism, and oxygen transport. Additionally, CD71 is highly expressed on the surface of rapidly proliferating cells, including those in the bone marrow, making it a key target for iron acquisition during cell growth and division. Inhibition of CD71 can occur through various mechanisms aimed at disrupting its function in iron uptake. One common approach involves blocking the binding of transferrin to CD71, thereby preventing the internalization of iron into cells. This can be achieved through the use of specific antibodies or small molecules that target the extracellular domain of CD71 and interfere with its interaction with transferrin. Another strategy involves inhibiting the endocytic process itself, either by disrupting the formation of clathrin-coated pits, which are necessary for CD71-mediated endocytosis, or by interfering with intracellular signaling pathways involved in the trafficking and recycling of CD71-containing vesicles. Additionally, modulation of CD71 expression levels on the cell surface through transcriptional or post-transcriptional mechanisms can also impact its function in iron uptake. Overall, inhibition of CD71 represents a strategy for conditions characterized by dysregulated iron metabolism, such as iron overload disorders or certain types of cancer.